Awarness & Innovation

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

about

The Project

Agaric Life Sciences Ltd. is an Italian-based Life Sciences company dedicated to the research and production of mushroom-based plant medicinesand associated consumer packaged goods as well as support services and tools for health and wellness benefits.

As health-conscious consumers increasingly seek for alternatives to traditional medicine and new therapeutic approaches to enhance health and wellness a tremendous market opportunity has opened for mushroom-based products and augmented-therapy tools.

MARKET OPPORTUNITY

Estimated $100+ billion global total addressable market for psychedelics.

The global market for functional mushrooms is forecasted to reach USD $34.3 billion by 2024, growing at a CAGR of 8.04% between 2022 and 2024.

The popularity of mushrooms is growing rapidly around the world, yet the market remains fragmented

Increasing interest in plant-based wellness alternatives to pharmacological medicines and treatments for health issues such as insomnia, depression, and anxiety.

OUR KEY ACTIVITIES

Mycelium to service

Developing the psychedelic value chain from mycelium to service tools.

Research and development

Research and development of products and tools to improve people's mental health and quality of life.

the program

Research & Development

Agaric’s current R&D Program is focused on:

Agaric’s mycelium-based patented technology will lead to the product development from a largely available standardized starting material that cannot be found in nature. Agaric plans to extend this proprietary technology to other mushroom varieties in a second phase.

As a result, Agaric mushroom-based products will meet high quality assurance standards via uniform controlled production protocols that follow the same standard as Good Manufacturing Process (GMP) for pharmaceuticals.
Research& Development Agaric’s breeding patented protocolcan be extended to other mushrooms’ subject of interest, i.epsilocybin mushrooms, for further product development.

It is anticipated that each product will be realized from a proprietary formulation which is developed under patented protocols.

When micro-dosed, Amanita Muscaria has anecdotally been shown to soothe the body, ease physical distress and help with sleeping .

In general, Agaric’s intention will be to formulate product with the aim of meet the demand in the cognitive health and mood improvement treatments.

VALUE PROPOSITION

for patented innovative production technologies and product solutions from standardized mycelium to the final consumer product.

by delivering high quality assurance standards via uniform controlled production protocols that follow the same standard as Good Manufacturing Practices (GMP) for pharmaceuticals.

for professional and personal use in the psychological wellness field.

for new models of care.

OUR CUSTOMERS

Product

Healthcare and pharmaceutical industry, distributors, and pharmacies.

Tools & Services

Healthcare professionals, Healthcare centers, Therapists, Research institutions, Individuals seeking to improve their quality of life.

FUTURE

Agaric Space

An augmented-therapy platform and app supporting plant medicine-induced wellness benefits and healing:

  • Advise on the best practices;

  • Tracking user´s psychological profiles and their dynamics across time;

  • Planning. Intention and Setting: Personalized audio and visual journeys for self-exploration;

  • Integrating. Integration guidance (audio by expert therapists and teachers), Integration services & Augmented integration tools.

contact us

For Further Informations